New Triple Cancer Therapy Shows Promising Response Rate
A new combination of drugs shows potential for adults with advanced extrapulmonary neuroendocrine carcinoma.
Updated on Oct. 23, 2026 in Cancer
A clinical trial reported a 69.8% objective response rate for a triple therapy combining surufatinib, serplulimab, and chemotherapy in patients with advanced extrapulmonary neuroendocrine carcinoma. These findings, which reached a data cutoff on May 30, 2026, suggest a new potential treatment avenue for this aggressive cancer.
Why it matters
Advanced neuroendocrine carcinomas are often challenging to treat, and this combination approach offers a potential new way to control tumor growth. Understanding these preliminary results helps patients and their physicians evaluate emerging options for managing advanced-stage disease.
In a Phase 1/2 trial involving 53 patients, the triple therapy achieved a 69.8% objective response rate and a 95.3% disease control rate among evaluable participants. Median progression-free survival reached 9.4 months, though these are preliminary findings from an ongoing study.
The players
ESMO Congress
A major international oncology conference where researchers share significant updates on cancer treatment and clinical trial data.
The details
The treatment combines surufatinib, which provides antiangiogenic and immunomodulatory effects, with the anti-PD-1 monoclonal antibody serplulimab and standard chemotherapy. Patients received a daily 250 mg dose of surufatinib and 300 mg of serplulimab every three weeks. Researchers assessed tumor progression every six weeks using standard RECIST 1.1 criteria to monitor treatment effectiveness.
Timeline
May 30, 2026: Data cutoff for the clinical trial results.
October 23, 2026: Presentation of trial findings at ESMO Congress in Madrid.
Health Landscape
This research expands the current treatment options for extrapulmonary neuroendocrine carcinoma beyond standard chemotherapy regimens. It aligns with broader trends of investigating combination therapies to improve outcomes in complex, high-grade neuroendocrine tumors.
Patients with advanced neuroendocrine carcinoma should speak with their oncology team about whether clinical trials involving immunotherapy combinations are appropriate for their specific case. Understanding the role of novel combination therapies is a valuable step in discussing comprehensive treatment plans with a physician.
The takeaway
Combination therapies involving immunotherapy and targeted agents are an emerging area of interest for treating advanced, aggressive cancers. Patients should keep track of their primary tumor site and discuss the latest clinical trial data for their diagnosis with their medical oncologist.
Further reading
For more on evolving research, visit our Cancer section.
More information
View the full clinical trial study details on the official registry.
